Merck KGaA's Cladribine Revival Smacks Of Desperation

In a surprise development, Merck KGaA has decided to file for approval of cladribine, the oral multiple sclerosis medicine it suspended in late-stage trials more than four years ago. It now says that, having evaluated new data and done additional analyses of the product's benefit-risk profile, it will file for approval in Europe in the first half of 2016, and that it is developing plans for filings in other markets.

In a surprise development, Merck KGaA has decided to file for approval of cladribine, the oral multiple sclerosis medicine it suspended in late-stage trials more than four years ago. It now says that, having evaluated new data and done additional analyses of the product's benefit-risk profile, it will file for approval in Europe in the first half of 2016, and that it is developing plans for filings in other markets.

Nevertheless, the drug looks like an also-ran in a highly competitive field, and the fact that it is Merck's best...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category